Difference between revisions of "Axitinib (Inlyta)"
m |
m (ASCO post article) |
||
| Line 2: | Line 2: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Tyrosine kinase inhibitor of multiple receptor tyrosine kinases, including vascular endothelial growth factor receptors VEGFR-1, VEGFR-2, and VEGFR-3, which interferes with tumor angiogenesis, growth, and cancer progression.<ref name="insert">[http://labeling.pfizer.com/ShowLabeling.aspx?id=759 Axitinib (Inlyta) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/axitinib.pdf Axitinib (Inlyta) package insert (locally hosted backup)]</ref> | + | Class/mechanism: Tyrosine kinase inhibitor of multiple receptor tyrosine kinases, including vascular endothelial growth factor receptors VEGFR-1, VEGFR-2, and VEGFR-3, which interferes with tumor angiogenesis, growth, and cancer progression.<ref name="insert">[http://labeling.pfizer.com/ShowLabeling.aspx?id=759 Axitinib (Inlyta) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/axitinib.pdf Axitinib (Inlyta) package insert (locally hosted backup)]</ref><ref>Matthew Stenger. [http://www.ascopost.com/articles/march-15-2012/what-you-need-to-know-about-axitinib/ What You Need to Know About Axitinib, New Agent for Treating Advanced Renal Cell Carcinoma]. ASCO Post, March 15, 2012, Volume 3, Issue 5.</ref> |
<br>Route: PO | <br>Route: PO | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
Revision as of 18:03, 3 April 2012
FDA approved 1/27/2012 Also known as AG013736.
General information
Class/mechanism: Tyrosine kinase inhibitor of multiple receptor tyrosine kinases, including vascular endothelial growth factor receptors VEGFR-1, VEGFR-2, and VEGFR-3, which interferes with tumor angiogenesis, growth, and cancer progression.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert[1].
Patient drug information
References
- ↑ 1.0 1.1 Axitinib (Inlyta) package insert
- ↑ Axitinib (Inlyta) package insert (locally hosted backup)
- ↑ Matthew Stenger. What You Need to Know About Axitinib, New Agent for Treating Advanced Renal Cell Carcinoma. ASCO Post, March 15, 2012, Volume 3, Issue 5.
- ↑ Axitinib (Inlyta) patient information (Pfizer)